GFM
SGMT icon

GF Fund Management’s Sagimet Biosciences SGMT Stock Holding History

GF Fund Management’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.6K Buy
689
+81
+13% +$451 ﹤0.01% 613
2025
Q4 		$3.6K Buy
+608
New +$4.37K ﹤0.01% 632

Other funds holding SGMT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

GF Fund Management's SGMT Position: Q1 2026 in Review

GF Fund Management increased its Sagimet Biosciences (SGMT) stake by 13% in Q1 2026, buying an estimated $451 and bringing the position to 689 shares worth $3.6K. The position accounts for ﹤0.01% of the portfolio, ranked #613.

GF Fund Management first reported a position in SGMT in Q4 2025 and has held it in 2 quarters since. 88 funds tracked by Wall St. Rank hold SGMT as of Q1 2026.

  • GF Fund Management held 689 shares of Sagimet Biosciences worth $3.6K as of Q1 2026.
  • GF Fund Management bought 81 Sagimet Biosciences shares in Q1 2026, an estimated $451.
  • Sagimet Biosciences made up ﹤0.01% of GF Fund Management's portfolio in Q1 2026, its #613 holding.
  • GF Fund Management first reported a position in Sagimet Biosciences in Q4 2025 and has held it in 2 quarters since.
  • 88 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q1 2026.

Based on GF Fund Management's 13F filing for Q1 2026, filed 15 Apr 2026.